From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Shore Cap on Amryt at 18.5p - target price increased from 35p to 88p!

By Tom Winnifrith | Saturday 25 March 2017


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Shore cap is House broker to Amryt Pharma (AMYT) so everything it writes cannot be said to be any way shape or form impartial. And since we own a shed load of the shares we are biased as hell too. Having said that this note is detailed and lifting the target price from 35p to 88p in light of recent news is pretty dramatic given that the shares were 18.5p on Friday when this "most excellent" research note came out.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 15:03:02